|Bid||154.00 x 800|
|Ask||168.00 x 1100|
|Day's Range||164.21 - 167.99|
|52 Week Range||90.14 - 196.00|
|Beta (3Y Monthly)||2.07|
|PE Ratio (TTM)||N/A|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|
Adaptimmune Therapeutics plc (ADAP) today announced that Adrian Rawcliffe, currently Chief Financial Officer (CFO) of the Company, will succeed James Noble as Chief Executive Officer (CEO). This transition will occur when James retires from his executive duties and transitions to a non-executive director role on the Company’s Board on September 1, 2019.
Founded in 1998, GW is a biopharmaceutical company focused on discovering, developing and commercializing novel therapeutics from its proprietary cannabinoid product platform in a broad range of disease areas. GW, along with its U.S. subsidiary Greenwich Biosciences, has received U.S. FDA approval for EPIDIOLEX (cannabidiol) oral solution for the treatment of seizures associated with Lennox-Gastaut syndrome (LGS) or Dravet syndrome in patients two years of age or older and which is now available by prescription in the U.S. The Company has submitted a regulatory application in Europe for the adjunctive treatment of seizures associated with LGS and Dravet syndrome.
LONDON, May 09, 2019 -- GW Pharmaceuticals plc and its U.S. subsidiary Greenwich Biosciences Inc. (NASDAQ: GWPH, GW, the Company or the Group), the world leader in the science,.
GW Pharmaceuticals plc and its U.S. subsidiary Greenwich Biosciences Inc. (NASDAQ: GWPH, GW, the Company or the Group), the world leader in the science, development, and commercialization of cannabinoid prescription medicines, today announced positive top-line results of a randomized, double-blind, placebo-controlled Phase 3 clinical trial of EPIDIOLEX® (cannabidiol or CBD) CV in the treatment of seizures associated with Tuberous Sclerosis Complex (TSC), a rare and severe form of childhood-onset epilepsy. In this trial, EPIDIOLEX met its primary endpoint, which was the reduction in seizure frequency compared to baseline of the Epidiolex 25 mg/kg/day dose group vs placebo (p=0.0009). Results for both the 25 and 50 mg/kg/day dose groups were similar, with seizure reductions of 48.6% and 47.5% from baseline respectively, vs 26.5% for placebo (50 mg/kg/day vs placebo, p=0.0018).
- Epidiolex U.S. Q1 net sales of $33.5m - - Positive Phase 3 pivotal results in Tuberous Sclerosis Complex, sNDA submission expected in Q4 2019 - - Conference call today at 4:30.
GW Pharmaceuticals plc (Nasdaq: GWPH, “GW,” “the Company” or “the Group”), the world leader in the development and commercialization of cannabinoid prescription medicines, along with its U.S. subsidiary Greenwich Biosciences, will present data from the pivotal Phase 3 trials of Epidiolex® (cannabidiol) oral solution, CV in Lennox-Gastaut syndrome (LGS) and Dravet syndrome, along with other supportive data, at the American Academy of Neurology (AAN) Annual Meeting, May 4-10, 2019, in Philadelphia.
GW Pharmaceuticals plc (Nasdaq: GWPH, “GW” or “the Company”), a biopharmaceutical company focused on discovering, developing and commercializing novel therapeutics from its proprietary cannabinoid product platform, will announce on May 6, 2019 its financial results for the quarter ending March 31, 2019. GW will also host a conference call the same day at 4:30 p.m. EDT. A replay of the call will also be available through the Company's website (www.gwpharm.com) shortly after the call.
HENDERSON, NV / ACCESSWIRE / April 16, 2019 / CBD is becoming a household name in the US. In a recent survey conducted with the Harris Poll, Quartz asked over 2,000 Americans about their use and perceptions ...
GW Pharmaceuticals plc (NASDAQ: GWPH, GW, the Company or the Group), the world leader in the development and commercialization of cannabinoid prescription medicines, today announced the appointment of Darren Cline as its new U.S. Chief Commercial Officer. Mr. Cline will lead the Epidiolex® U.S. commercial organization and is expected to start on April 22, 2019.
HENDERSON, NV / ACCESSWIRE / March 21, 2019 / The electricity consumption of cannabis grow houses is staggering when compared to business and residential use. In 2015, the average electricity consumption ...
CORAL GABLES, FL / ACCESSWIRE / March 20, 2019 / The marijuana stock market has exhibited great promise in the month of March, resulting in the excitement surrounding the cannabis industry. As we look to the future, these smaller companies may play a role in securing potential opportunities for the cannabis industry. ParcelPal Technology Inc (PTNYF) (PKG), Curaleaf Holdings Inc (CURLF) (CURA.CN), Zynerba Pharmaceuticals Inc (ZYNE), and GW Pharmaceuticals plc (GWPH) represent 4 marijuana stocks getting a boost from today's headlines.
GW Pharmaceuticals plc (NASDAQ: GWPH, GW, the Company or the Group), the world leader in the development and commercialization of cannabinoid prescription medicines, today announced that GW Research Ltd. has entered into a definitive agreement to sell its Rare Pediatric Disease Priority Review Voucher (PRV) for $105,000,000. GW was awarded the voucher under a U.S. Food and Drug Administration (FDA) program intended to encourage the development of treatments for rare pediatric diseases. GW Research Ltd. received the PRV when EPIDIOLEX® (cannabidiol) was approved by the FDA for the treatment of seizures associated with Lennox-Gastaut Syndrome or Dravet syndrome, two rare, severe childhood-onset epilepsies.
Multi-billion-dollar industries are already being uprooted by cannabis, including beverages, alcohol, beer, sports drinks, pharmaceuticals, tobacco, and the $3.2 trillion wellness industry, as the cultural renaissance just gets underway. It's just starting to disrupt countless, multi-billion-dollar industries, especially the $4.2 trillion wellness industry. The Yield Growth Corporation (BOSS)(BOSQF), for example, has engaged the Faculty of Pharmaceutical Sciences at the University of British Columbia (UBC) to identify and quantify anti-inflammatory and other bioactive compounds in its hemp root oil derived by Yield Growth's proprietary extraction methods.
HENDERSON, NV / ACCESSWIRE / March 12, 2019 / Year to date, the Global Cannabis Stock Index is up almost 50% in less than three months. It's safe to say investors are bullish on the cannabis. Here are ...
HENDERSON, NV / ACCESSWIRE / March 6, 2019 / OxyContin maker Purdue Pharma is exploring filing for bankruptcy as one of its options to address potentially significant liabilities from thousands of lawsuits ...
CORAL GABLES, FL / ACCESSWIRE / February 27, 2019 / When investors look at marijuana stock market, they tend to pick out some of the companies at the top of the industry. If these trends continue, this could lead to an increase in investor excitement surrounding the cannabis industry. Leafbuyer Technologies Inc (OTC:LBUY), GW Pharmaceuticals plc (GWPH), Isodiol International Inc (ISOLF), and Tilray Inc (TLRY) are four marijuana stocks getting a boost from today's headlines.
– Epidiolex® (cannabidiol) oral solution (CV), first FDA-approved plant-derived cannabinoid medicine, launched in the U.S. in November to high awareness and demand – – GW moves.
- Leerink Partners 8th Annual Global Healthcare Conference on February 28, 2019 -- Cowen and Company 39th Annual Health Care Conference on March 11, 2019 - LONDON and.
CORAL GABLES, FL / ACCESSWIRE / February 22, 2019 / The marijuana stock market has taken over media headlines over the course of the past few years, during the course of which top players in the cannabis industry have seen a substantial increase in investor interest. Considering the innovative approaches companies in the sector are taking to develop high-quality products for cannabis consumers, it makes perfect sense that this had resulted in the excitement surrounding the market. In addition to the positive shift in public opinion, lawmakers across the global cannabis space are putting forth legislation in favor of legalizing marijuana.
For the future of the industry to be secured, lawmakers need to press onward with passing this type of legislation, because, ultimately, this will allow companies in the sector to continue operating and developing novel products to distribute throughout the domestic cannabis market, rather than in a select few states. Nabis Holdings (INNPF) (NAB), Canopy Growth Corp (CGC) (WEED), GW Pharmaceuticals plc (GWPH), and CV Sciences Inc (CVSI) are four cannabis companies worth keeping on your radar. Nabis Holdings (INNPF) (NAB) is a Canadian investment company determined to make strategic investments in a multitude of high-quality cash flowing assets across an array of businesses in the cannabis sector, primarily in U.S. limited license states.
HENDERSON, NV / ACCESSWIRE / February 13, 2019 / One you should research right away, BioRestorative Therapies, Inc. (BRTX) , a life sciences company focused on stem cell-based therapies, is developing ...
CORAL GABLES, FL / ACCESSWIRE / February 8, 2019 / Marijuana stocks have become one of the hottest topics in the news over the course of the past few years. Recently, the cannabis industry has seen an increase in capital enjoyed by companies working to optimize and innovate products for the adult-use recreational cannabis market. As it relates to positive legislation brought forth by lawmakers, as many as 33 states in the U.S. have passed laws allowing for the use of cannabis, with many of those offering recreational cannabis as well.
GW Pharmaceuticals plc (Nasdaq: GWPH, “GW” or “the Company”), a biopharmaceutical company focused on discovering, developing and commercializing novel therapeutics from its proprietary cannabinoid product platform, will announce on 26 February, 2019 its financial results for the quarter ending 31 December, 2018. This is a transition period as GW will be moving to a new fiscal year-ending 31 December following this report on Form 10K-T. GW will also host a conference call the same day at 4:30 p.m. EST. A replay of the call will also be available through the Company's website (www.gwpharm.com) shortly after the call.
HENDERSON, NV / ACCESSWIRE / February 6, 2019 / Cannabis and Biotech are in the middle of a massive comebacks, several small-cap plays in the sectors are prime for investors, here's a few to start researching. ...
HENDERSON, NV / ACCESSWIRE / February 5, 2019 / Below are some healthcare plays starting to gain investor interest that could breakout at any time. Do your research now. One of the best examples of the ...